✦ LIBER ✦

A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in Δ F508-Homozygous Cystic Fibrosis Patients

✍ Scribed by RUBENSTEIN, RONALD C.; ZEITLIN, PAMELA L.

Book ID: 120210527
Publisher: American Thoracic Society
Year: 1998
Tongue: English
Weight: 93 KB
Volume: 157
Category: Article
ISSN: 1073-449X
DOI: 10.1164/ajrccm.157.2.9706088

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical evaluation of VX-809, a novel i

Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del–CFTR mutation

✍ J.P. Clancy; G. Spencer-Green 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 52 KB

4 Prevalence of ΔF508 mutation in patien

4 Prevalence of ΔF508 mutation in patients with cystic fibrosis in a miscegenated population of the Brazilian Northeast

✍ Souza, E.L.; Pimentel, C.S.S.; Sena, N.A.; Bittencourt, P.H.; Mota, L.R.; Lima, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Cystic fibrosis patients with mutation 1

Cystic fibrosis patients with mutation 1949del84 in exon 13 of the CFTR gene have a similar clinical severity as ΔF508 homozygotes

✍ V. Nunes; T. Casals; A. Gaona; G. Antiñolo; J. Ferrer-Calvete; J. Pérez-Frias; E 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB

The majority of the identified cystic fibrosis (CF) mutations are very uncommon in the total patient population, making the correlation between the clinical presentation and the molecular alterations difficult. The largest deletion that has been described so far in C F is of 84 bp in exon 13, which